CARLSBAD, Calif., May 23, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a general corporate update in conjunction with its 2011 Annual Meeting of Stockholders and Open House on Thursday, June 16 at 2:15 p.m. Pacific Time in Carlsbad, CA. The agenda for the meeting is as follows:2:00 p.m. – 2:15 p.m. Annual Meeting of Stockholders (only for stockholders of record as of April 20, 2011)2:15 p.m. – 3:00 p.m. Corporate Presentation – Stanley T. Crooke, Isis Chairman and Chief Executive Officer3:00 p.m. – 5:00 p.m. Poster PresentationA live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.
ABOUT ISIS PHARMACEUTICALS, INC.Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 24 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis has designed and executed a patent strategy that has provided the Company with strong and extensive protection for Isis' drugs and technology. Additional information about Isis is available at www.isispharm.com.
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved